The APTIMA HIV-1 Quant Assay (APT-Quant) is FDA-approved for quantification of HIV-1 plasma RNA from 30-107 copies (cp)/ml. Outside the U.S. quantitative results can also be interpreted qualitatively. We evaluated the performance of APT-Quant for HIV-1 RNA quantification and for off-label diagnostic use.
One AccuSpan HIV-1 RNA linearity panel (LP) (n=30 or n=43 with two kit lots), U.S. samples from early HIV-1 infections collected from 46 seroconverters (n=420, subtype B), Cameroonian antibody-positive samples (n=113, non-B subtypes and Group O), and HIV-negative samples (n=478) were tested with APT-Quant on the Panther system. Volume permitting, samples were also tested with APTIMA HIV-1 RNA Qualitative (APT-Qual), Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 Test v2.0 (Roche viral load (VL)), and Abbott RealTi[i]m[/i]e HIV-1 (Abbott VL) assays. We analyzed agreement between APT-Quant and other FDA-approved VL assays by linear regression and concordance correlation coefficient, calculated specificity in APT-Qual-nonreactive/HIV-1 WB-negative (HIV-negative) specimens and evaluated test reproducibility (standard deviation) using two kit lots with LPs. We analyzed APT-Quant for diagnostic use by comparing to APT-Qual results (McNemar’s paired test).
Table shows agreement between APT-Quant and other VL assays. Using LPs, the standard deviation ranged from 0.021-0.113 (lot 1) and 0.015-0.489 (lot 2) with high variability at ~3 log(cp/ml). APT-Quant specificity was 99.79% [CI: 98.82- 99.96%]. APT-Quant detected virus in 34 more samples than APT-Qual in early stages of infection (n=417, p<0.0001) and in all 105 APT-Qual-reactive Cameroonian samples. Of 228 samples from seroconverters, APT-Quant detected virus in 180 samples, Roche VL in 163, and APT-Qual in 157. Both APT-Qual and Quant missed two infections with Roche VLs <20 cp/ml and one with 23 cp/ml. APT-Quant was nonreactive in two samples with VLs of 29 and 32 cp/ml. Controls failed in one run for LP and three panel members >7 log(cp/ml) were invalid needing 1:100 dilution (kit lot 2).
APT-Quant showed good agreement with Roche and Abbott VL assays in Group M and O specimens and with high sensitivity and specificity. APT-Quant performance exceeds APT-Qual for detecting infections with low VL in early stages of infection and established infections. The APT-Quant assay could also be used for diagnostics if properly validated in a laboratory or via an FDA diagnostic claim.